Illinois Department of Commerce and Economic Opportunity
607 East Adams, Springfield, IL, 62701, United States
Overview
Illinois Department of Commerce & Economic Opportunity aims to promote equal economic opportunities throughout Illinois. DCEO works to strengthen Illinois' reputation as a global economic powerhouse by attracting and supporting major job creators, investing in communities, strengthening Illinois' world-class workforce, fostering innovation, and ushering in the new clean energy economy.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 2
- Active investors
- 0
Investment portfolio
- SyntaxBio
Participated · Series A · Jun 2026
Syntax Bio develops a CRISPR-based Cellgorithm™ platform intended to program and accelerate stem cell differentiation to enable scalable cell therapies. The company is advancing a pancreatic beta cell therapy candidate for type 1 diabetes and plans to fund preclinical proof-of-concept studies with proceeds from its expanded Series A. Syntax Bio has publicly reported a collaboration with Mayo Clinic, received a grant from Breakthrough T1D, and published peer-reviewed research in Science Advances describing its technology. Financially, the company expanded its Series A to $14.4 million, bringing total funding to over $25 million. Leadership changes accompanying the financing include a CEO who joined in 2025 and new executive, board, and scientific advisory appointments to support translational development and commercialization. The company positions its platform as a way to replace slow, labor-intensive differentiation processes with a programmable approach to generate functional cells at scale.
- Prenosis
Participated · Series A · Feb 2026
Prenosis develops AI-powered diagnostic and therapeutic tools that tailor care to each patient’s unique biological profile. Its core Immunix platform aggregates deep biological data to create diagnostics such as the Sepsis ImmunoScore, the first FDA-authorized AI test for sepsis. The company aims to commercialize ImmunoScore while continuing to expand its portfolio of biology-based diagnostics. Plans include deploying the platform in up to 40 academic medical centers to establish a precision-medicine clinical-trial network, enabling rapid recruitment of patients with specific biological signatures. Led by CEO Bobby Reddy, Jr., PhD, Prenosis positions itself at the intersection of data science, biology, and clinical practice to improve outcomes in critical conditions. The new capital will accelerate product rollout and broaden clinical integration efforts, supporting the company’s mission to personalize critical-care medicine.
Team
No current team members are available.